Mario Cipollini hospitalised again as heart problems persist for cycling legend
Mario Cipollini hospitalised again as heart problems persist for cycling legend
Mario Cipollini hospitalised again as heart problems persist for cycling legend
Former cycling champion Mario Cipollini is once again dealing with heart problems. The 58-year-old, known for his sprinting prowess, has been hospitalised in Ancona, Italy. In a recent video, he shared that his heart continues to cause him difficulties.
Cipollini's heart troubles are not new. In 2019, he underwent surgery for viral myocarditis, a serious condition causing inflammation of the heart muscle. Last year, doctors fitted him with a pacemaker to help regulate his heartbeat.
Now, the Italian cyclist finds himself back in hospital. He admitted he would prefer to be cycling in the hills of Lucca, his hometown, rather than receiving treatment. Despite the setback, he remains hopeful that a defibrillator won't be necessary.
No further updates on his medical condition have been made public since his latest hospital stay. Cipollini has promised to keep fans informed about his health as more details emerge.
The cycling legend's ongoing heart issues highlight the challenges he has faced since retiring. His latest hospitalisation follows years of medical interventions, including surgery and a pacemaker. For now, fans await further news on his recovery and treatment progress.
Garlic, Vitamin C, and Chlorophyll Team Up for Heart Health Breakthrough
Could a simple blend of garlic, vitamin C, and chlorophyll be the key to a healthier heart? New findings reveal surprising benefits for blood pressure and beyond.
Chuck Norris, 86, hospitalized after medical emergency in Hawaii
From Walker, Texas Ranger to recent films, Norris never slowed down—until now. Fans worldwide await news after his sudden hospitalization.
Blood Test Breakthrough Could Detect Hidden Artery Disease Years Earlier
A simple blood test could soon reveal invisible plaque buildup—long before it triggers a deadly event. Machine learning cracked the code in 45,000 patients' data.
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
A triple-hormone drug could redefine diabetes care. Early data shows retatrutide outperforms competitors—but will regulators agree?